Opening stock page...
Fetching company snapshot, pricing, and intelligence.
Intelligence coverage: 55%
Basic profile, financials, and market data are shown below. Deep research is building in the background.
AI confidence 70% · prior close shown (market closed)
Limited proprietary earnings coverage for TELO yet — signals will sharpen as filings and earnings are ingested.
Pipeline evidence · 0d ago
TELO's AlphaOS Signals
Upgrade to Pro for validated historical pattern analysis on TELO.
Free accounts see more of this; Premium sees all of it.
Updated
What happened recently for Telomir Pharmaceuticals, Inc. (TELO) — events, not interpretation.
Research & analysis only — not investment advice.
Investment snapshot
TELO's AI investment thesis
Upgrade to Premium for TELO's full multi-agent investment thesis.
Free accounts see more of this; Premium sees all of it.
Unified data coverage and cross-signal highlights — market, SEC, earnings, opportunity
Strengthen intelligence
Prior close
$1.22
Market cap
$83.91M
Profitable
No
Net income
$-10.41M
FY Dec 31, 2025
Loading Wall Street consensus…
Loading earnings intelligence…
Building technical intelligence snapshot — check back shortly.
Loading market context…
No price history. Sync market data to load charts.
Loading SEC filing intelligence…
No filings ingested yet.
US equity research on AlphaOS
Investment Snapshot above is the primary AlphaOS analysis for Telomir Pharmaceuticals, Inc. — structured signals and evidence from proprietary pipelines, not an encyclopedia overview.
Research & analysis only — not investment advice. Price, charts, and filings are above.
Follow Telomir Pharmaceuticals, Inc. through AlphaOS's knowledge graph — themes, peers, beneficiaries, earnings, and research answers.
Connected companies and research pages from the AlphaOS knowledge graph.